Impact of Metabolism in on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
The immune system and metabolism are highly integrated and multilevel interactions between metabolic system and T lymphocyte signaling and fate exist. Accumulating evidence indicates that the regulation of nutrient uptake and utilization in T cells is critically important for the control of their differentiation and manipulating metabolic pathways in these cells can shape their function and survival. This review will discuss some potential cell metabolism pathways involved in shaping T lymphocyte function and differentiation. It will also describe show subsets of T cells have specific metabolic requirements and signaling pathways that contribute to their respective function. Examples showing the apparent similarity between cancer cell metabolism and T cells during activation are illustrated and finally some mechanisms being used by tumor microenvironment to orchestrate T-cell metabolic dysregulation and the subsequent emergence of immune suppression are discussed. We believe that targeting T-cell metabolism may provide an additional opportunity to manipulate T-cell function in the development of novel therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 1×
“Indeed, tumor microenvironment components form a very complex immunosuppressive network in cancer (148), lead to metabolic and immune checkpoints abrogation, which limits T-cell activation and induces T-cell dysfunction (149, 150).”
BackgroundThe Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“Interaction of PD-1 with its ligand programmed death ligand-1 (PD-L1), allows the tumor to evade immune system by inhibiting T-cell function (168, 169).”
BackgroundThe Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150 · cited 1×
“Cancer cells use the Warburg effect as strategic metabolic adaptation to satisfy their urgent requirements for growth and proliferation under tumor microenvironmental limitations for oxygen and nutrients (113, 114).”
BackgroundRegulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 1×
“As a consequence, cancer cells thereby gain selective growth and survival (112).”
BackgroundOtto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427 · cited 1×
“This metabolic program was recognized since 1920s by Otto Warburg as the “Warburg effect” (102, 103), a strategic metabolic adaptation enhancing rapid tumor growth, proliferation, and to dampen antitumor immunity, thus representing one additional hallmark of cancers.”
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331 · cited 3×
“The same effects were reported after PD-L1 blockade or RNA interference directed against PD-L1 in cultured tumor cells (152).”
BackgroundMolecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“Tryptophan degradation is one of a resistance mechanisms adopted by tumors to avoid immune suppression (92, 93).”
BackgroundOverview of the immune response
Chaplin, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.980 · Cited by 2,235 · cited 1×
“Teff could be divided into cytolytic T cells, secreting granzyme B, perforin, interferon-γ (IFN-γ), into helper T cells (Th) including the type-1 (Th1), type-2 (Th2), and type-17 (Th17) producing characteristic cytokines or into regulatory T cells (Treg) (28, 29).”
BackgroundThe transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation
Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L. L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.021 · Cited by 2,140 · cited 2×
“Furthermore, c-Myc is responsible for enhanced glutaminolysis by inducing glutamine transporters and glutaminase1 expression to sustain cell growth and proliferation (60, 61).”
BackgroundGao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Michalek, R. D., Gerriets, V. A., Jacobs, S. R., Macintyre, A. N., MacIver, N. J., Mason, E. F., Sullivan, S. A., Nichols, A. G., & Rathmell, J. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003613 · Cited by 2,091 · cited 1×
“Treg favor FA catabolism via b-oxidation and prioritize oxidative ATP to meet their energetic demands, an important metabolic phenotype for the differentiation of Treg (38).”
BackgroundCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Shi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R., & Chi, H. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110278 · Cited by 1,803 · cited 2×
“HIF-1α is reported to play a more selective role in inflammatory Th17 CD4 T-cell subsets (42) and cytolytic CD8 T (58).”
BackgroundL-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775 · cited 2×
“Interestingly, recent study showed that increased arginine levels display improved survival capacity of T memory cells and antitumor activity (95).”
BackgroundGlutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Metabolic Pathways in Immune Cell Activation and Quiescence
Pearce, E. L., & Pearce, E. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.04.005 · Cited by 1,692 · cited 2×
“The differences in functional and phenotypic characteristics of quiescent T cells and activated T cells are supported by differential metabolic requirements (17).”
BackgroundSpranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625 · cited 1×
“It is likely that T cells undergo immune suppressive networks that impair their specific functions and thereby enable tumor escape (145, 146).”
BackgroundControl of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595 · cited 1×
“In addition, HIF-1α appears to influence the balance of Th17:Treg cells (65).”
BackgroundEnhancing CD8 T-cell memory by modulating fatty acid metabolism
Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559 · cited 1×
“Several studies revealed that maintaining mitochondrial mass is critical for Tm cells development since it offers the opportunity to use a wide range of substrates responsible for energy generation, like fatty acids (46, 47).”
BackgroundMitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development
van der Windt, G. J. W., Everts, B., Chang, C.-H., Curtis, J. D., Freitas, T. C., Amiel, E., Pearce, E. J., & Pearce, E. L. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.007 · Cited by 1,540 · cited 1×
“Several studies revealed that maintaining mitochondrial mass is critical for Tm cells development since it offers the opportunity to use a wide range of substrates responsible for energy generation, like fatty acids (46, 47).”
BackgroundTumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376 · cited 18×
“This metabolic adaptation is mainly orchestrated through the upregulation of the transcription factor, HIF-1α.”
BackgroundInfluentialSena, L. A., Li, S., Jairaman, A., Prakriya, M., Ezponda, T., Hildeman, D. A., Wang, C.-R., Schumacker, P. T., Licht, J. D., Perlman, H., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.020 · Cited by 1,338 · cited 1×
“However, excessive ROS levels are toxic for T cells and leads to apoptosis (43).”
BackgroundRodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Metabolic Regulation of T Lymphocytes
MacIver, N. J., Michalek, R. D., & Rathmell, J. C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095956 · Cited by 1,244 · cited 8×
“Am J Respir Cell Mol Biol (2010) 42(1):123–8.”
BackgroundInfluentialHypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · cited 1×
“Recently, preclinical studies demonstrate the efficiency of two IDO inhibitors to attenuate tumor growth (185, 186).”
BackgroundRegulation and function of mTOR signalling in T cell fate decisions
Chi, H. (2012) · Nature Reviews Immunology · doi:10.1038/nri3198 · Cited by 1,035 · cited 1×
“Under tumoral context, the balance between Teff and Treg may be directly disturbed when AMPK signaling pathway inhibits mTORC (56, 160).”
BackgroundCD4 + Regulatory T Cells Control T H 17 Responses in a Stat3-Dependent Manner
Chaudhry, A., Rudra, D., Treuting, P., Samstein, R. M., Liang, Y., Kas, A., & Rudensky, A. Y. (2009) · Science · doi:10.1126/science.1172702 · Cited by 1,000 · cited 1×
“Hence, Treg obstruct Teff activity and suppress immunity, showing a poor prognosis in many cancers (30).”
BackgroundRegulation of mammalian nucleotide metabolism and biosynthesis
Lane, A. N., & Fan, T. W.-M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv047 · Cited by 959
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J. G., Yu, Z., Roychoudhuri, R., Palmer, D. C., Muranski, P., Karoly, E. D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69589 · Cited by 952 · cited 1×
“In fact, metabolism shifts to glycolysis to support rapid growth and to biosynthesis for differentiation into effector T cells (Teff) (1, 20, 21) (Figure 1A).”
BackgroundArts, R. J. W., Novakovic, B., ter Horst, R., Carvalho, A., Bekkering, S., Lachmandas, E., Rodrigues, F., Silvestre, R., Cheng, S.-C., Wang, S.-Y., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.008 · Cited by 930
De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells
Berod, L., Friedrich, C., Nandan, A., Freitag, J., Hagemann, S., Harmrolfs, K., Sandouk, A., Hesse, C., Castro, C. N., Bähre, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3704 · Cited by 927
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894 · cited 18×
“This metabolic adaptation is mainly orchestrated through the upregulation of the transcription factor, HIF-1α.”
BackgroundInfluentialBengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
Carr, E. L., Kelman, A., Wu, G. S., Gopaul, R., Senkevitch, E., Aghvanyan, A., Turay, A. M., & Frauwirth, K. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903586 · Cited by 830
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · cited 1×
“Surface expressed PD-L1 is important for Akt/mTOR signaling to promote mTOR activity and glycolytic metabolism in tumor cells (172, 173).”
BackgroundT cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752 · cited 1×
“T cells dramatically reduced glycolysis and become unable to produce cytokines and to develop into tumor-specific Teff cells, leading to a state of anergy (155) (Figure 1B).”
BackgroundLKB1 and AMP-activated protein kinase control of mTOR signalling and growth
Shaw, R. J. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01972.x · Cited by 644 · cited 1×
“Under tumoral context, the balance between Teff and Treg may be directly disturbed when AMPK signaling pathway inhibits mTORC (56, 160).”
Finlay, D. K., Rosenzweig, E., Sinclair, L. V., Feijoo-Carnero, C., Hukelmann, J. L., Rolf, J., Panteleyev, A. A., Okkenhaug, K., & Cantrell, D. A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112607 · Cited by 596 · cited 18×
“This metabolic adaptation is mainly orchestrated through the upregulation of the transcription factor, HIF-1α.”
BackgroundInfluentialMetabolic switching and fuel choice during T‐cell differentiation and memory development
van der Windt, G. J. W., & Pearce, E. L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01150.x · Cited by 563 · cited 1×
“Following T-cell activation through efficient TCR signaling, the uptake and biosynthesis of amino acids or amino acid transporter expression are dramatically increased (82, 83).”
BackgroundFeron, O. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.06.025 · Cited by 559 · cited 1×
“During glycolysis, glucose is not fully oxidized in the mitochondria but rather broken down into pyruvate that is converted into lactate even though in presence of sufficient oxygen (81).”
BackgroundCD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability
van der Windt, G. J. W., O’Sullivan, D., Everts, B., Huang, S. C.-C., Buck, M. D., Curtis, J. D., Chang, C.-H., Smith, A. M., Ai, T., Faubert, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221740110 · Cited by 523
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479
Discrete Generation of Superoxide and Hydrogen Peroxide by T Cell Receptor Stimulation
Devadas, S., Zaritskaya, L., Rhee, S. G., Oberley, L., & Williams, M. S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20010659 · Cited by 458 · cited 1×
“However, although high levels of ROS impair T-cell metabolism and function, ROS at a low or moderate-concentration is indispensable for T-cell activation and effector function (165).”
BackgroundmTOR , metabolism, and the regulation of T‐cell differentiation and function
Waickman, A. T., & Powell, J. D. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01152.x · Cited by 420 · cited 1×
“PD-1 signaling is associated with reduced cMyc expression and inhibition of activity of the PI3K/Akt/mTOR pathway, necessary for effector function (50, 170, 171).”
BackgroundReactive Oxygen Species Regulate T Cell Immune Response in the Tumor Microenvironment
Chen, X., Song, M., Zhang, B., & Zhang, Y. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1580967 · Cited by 326 · cited 1×
“It has been demonstrated that high level of ROS in the tumor microenvironment downregulates T-cell activity and enhanced T-cell apoptosis, inhibiting subsequently antitumor immune response (164).”
BackgroundRos, S., & Schulze, A. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-8 · Cited by 269
AMPK α1: A glucose sensor that controls CD 8 T ‐cell memory
Rolf, J., Zarrouk, M., Finlay, D. K., Foretz, M., Viollet, B., & Cantrell, D. A. (2013) · European Journal of Immunology · doi:10.1002/eji.201243008 · Cited by 245
The metabolic life and times of a T‐cell
Michalek, R. D., & Rathmell, J. C. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00911.x · Cited by 186 · cited 1×
“To maintain a proper response, T-cell activation requires the upregulation of both glucose and amino acid transporters (1, 76).”
BackgroundIron and Immunity: Immunological Consequences of Iron Deficiency and Overload
Cherayil, B. J. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0095-9 · Cited by 170
Glycolysis inhibitors for anticancer therapy: A review of recent patents
Sheng, H., & Tang, W. (2016) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892811666160415160104 · Cited by 71 · cited 9×
“Upon antigen encounter, upregulation of aerobic glycolysis in extensive proliferating T cells is accompanied with glutaminolysis, PPP, not only to support ATP generation, but also to enhance biosynthesis of crucial intermediates and precursors necessary for subsequent macromolecules that are incorporated into cellular…”
BackgroundInfluentialWei, J., Zhang, M., & Zhou, J. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.06.002 · Cited by 63 · cited 9×
“However, excessive ROS levels are toxic for T cells and leads to apoptosis (43).”
BackgroundInfluentialAsymmetric cell division during T cell development controls downstream fate
Pham, K., Shimoni, R., Charnley, M., Ludford-Menting, M. J., Hawkins, E. D., Ramsbottom, K., Oliaro, J., Izon, D., Ting, S. B., Reynolds, J., et al. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201502053 · Cited by 39 · cited 1×
“Interestingly, T-cell differentiation to effectors or Tm cells is governed in part by asymmetric partitioning of fate determining proteins (51, 52).”
BackgroundTCR-signaling events in cellular metabolism and specialization
Chisolm, D. A., & Weinmann, A. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00292 · Cited by 26
Cited by
Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?
Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E. H., Cohen, A. A., Witkowski, J. M., & Franceschi, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01960 · Cited by 1,364
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020) · Current Oncology · doi:10.3747/co.27.5223 · Cited by 954
The role of lipids in cancer progression and metastasis
Martin-Perez, M., Urdiroz-Urricelqui, U., Bigas, C., & Benitah, S. A. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.023 · Cited by 563
Fates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism
Angajala, A., Lim, S., Phillips, J. B., Kim, J.-H., Yates, C., You, Z., & Tan, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01605 · Cited by 455
Metadata
- Authors
- Kouidhi, S., Elgaaied, A. B., & Chouaib, S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-03-13
- Volume
- 8
- Pages
- 270-270
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2593337891
- Cited by
- 138
- References
- 59
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.